BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates
Ocular Therapeutix: Q4 Earnings Snapshot
SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49 th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™...
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack
BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...
Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA ® while at Regeneron Most recently served as...
3 Cash-Burning Stocks We’re Skeptical Of
1 Healthcare Stock to Consider Right Now and 2 We Find Risky
3 Reasons OCUL is Risky and 1 Stock to Buy Instead